Skip to content

Cytokines and Cognitive Decline in Alzheimer's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01351142
Enrollment
133
Registered
2011-05-10
Start date
2009-11-30
Completion date
Unknown
Last updated
2016-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

Amyloid plaques and neurofibrillary tangles are the 2 well-known etiopathological hallmarks of Alzheimer's disease (AD). Beside these 2 lesions, inflammation response is described in the brain of patients with AD. The main objective of our study is to analyse the correlation between the value of plasma cytokines (interleukin 1, 6, TNFα and chemochine Rantes) and the rapidity of the cognitive decline in AD over a 2-year follow-up. Secondary objectives include: * the predictive value of the cytokines on the cognitive decline after 6 months and one year of follow-up., of the patients include 150 patients with AD (MMSE: 16-25) * correlation between plasma cytokines levels and expression of the protein kinase PKR (involved in death cell) in blood mononuclear cells.

Interventions

OTHERblood test and cognitive tests

Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years

Sponsors

Poitiers University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Alzheimer's disease (AD)patients * MMSE score: 16-25 * Written informed consent

Exclusion criteria

* AD patients with specific treatment for AD before inclusion MMSE score under 16 or over 25 at inclusion * patients with anti-inflammatory drugs (non steroids or corticosteroids) or immunosuppressive agents * Patients with acute disease (infectious disease, rheumatologic disease) or chronic disease (malignancy, infectious, rheumatologic disease) that could interact with plasma cytokines level * Patients with a life threatening disease

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026